Genomes and Genes
Affiliation: Institut Gustave Roussy
- Cutaneous side-effects of kinase inhibitors and blocking antibodiesCaroline Robert
Department of Medical Oncology, Dermatology Unit, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94801Villejuif Cedex, France
Lancet Oncol 6:491-500. 2005..Elucidation of this connection could lead to the identification of crucial predictive factors for tumour response...
- Tyrosine kinase inhibition and grey hairCaroline Robert
Lancet 361:1056. 2003
- Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanomaBruce Elliott
Royal Surrey County Hospital Guildford, Guildford, United Kingdom
Clin Cancer Res 13:3825-30. 2007..The aim of this study was to investigate the prognostic importance of the maximal density of mature DCs in SLNs...
- [Cutaneous side effects of antiangiogenic agents]Caroline Robert
Service de Dermatologie, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94800 Villejuif
Bull Cancer 94:S260-4. 2007..It will help us understanding better skin pathophysiology, but, most of all, it will lead to more efficient symptomatic treatment for our patients...
- Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitorJulien Autier
Dermatology Unit, Gustave Roussy Institute, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
Arch Dermatol 144:886-92. 2008..To provide an accurate description and to evaluate the incidence and severity of cutaneous reactions induced by sorafenib tosylate, a new oral multikinase inhibitor...
- [Management of side effects of targeted therapies in renal cancer: cutaneous side effects]Caroline Robert
Institut Gustave Roussy, Service de Dermatologie, 39, rue Camille Desmoulins, 94805 Villejuif Cedex, France Electronic address
Bull Cancer 98:S35-46. 2011..This guideline describes the incidence, clinical presentation and treatment of dermatologic side effects that develop with the use of targeted therapies (sunitinib, sorafenib, pazopanib, bevacizumab, everolimus, temsirolimus). ..
- Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised studyCaroline Robert
Institute Gustave Roussy, Paris, France
Lancet Oncol 14:733-40. 2013..This study was designed to look for a signal of improved efficacy by comparing the combination of selumetinib and dacarbazine with dacarbazine alone...
- Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease controlCaroline Robert
Institut Gustave Roussy, Villejuif, France
Clin Cancer Res 19:2232-9. 2013..Here, outcomes for these patients concerning baseline characteristics, best overall response, and disease control rate are assessed and considered with respect to the overall study population...
- Advances in the management of cutaneous toxicities of targeted therapiesCaroline Robert
Institute Gustave Roussy, Villejuif, France
Semin Oncol 39:227-40. 2012..We will review the skin side effects of EGFR, VEGFR, KIT, platelet-derived growth factor receptor (PDGFR), and BCR-ABL inhibitors, as well as mTOR inhibitors...
- What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?Caroline Robert
Institute Gustave Roussy, 94805 Villejuif Cedex, France
Oncologist 14:848-61. 2009..However, the true advantage of these new drugs may depend largely on the characterization of predictive biomarkers of activity and subsequent targeting of responsive patients...
- [Anti-CTLA-4 monoclonal antibody: a major step in the treatment of metastatic melanoma]Caroline Robert
Institut Gustave Roussy, Villejuif, France
Med Sci (Paris) 27:850-8. 2011..The challenges are now to identify biomarkers able to predict ipilimumab benefit and to know how to use ipilimumab in combination with new targeted therapies of melanoma in order to optimize the treatment efficacy...
- [What is new in oncodermatology?]C Robert
Service de Dermatologie, Institut Gustave Roussy, Villejuif, France
Ann Dermatol Venereol 135:S354-9. 2008..Besides melanoma, the scoop of the year was the discovery of a defective oncogenic polyomavirus which is very likely to be responsible for Merkel cell carcinoma...
- Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1Jean Philippe Arnault
Department of Medical Oncology and Pathology, Institute Gustave Roussy, Villejuif, France
Clin Cancer Res 18:263-72. 2012..We carried out a clinical, pathologic, and molecular study of skin lesions occurring in patients receiving sorafenib...
- Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15RalphaSophie Viaud
Institut National de la Sante et de la Recherche Medicale, Unité 805, Villejuif, France
PLoS ONE 4:e4942. 2009..Altogether, these data provide a mechanistic explanation on how Dex may stimulate non MHC restricted-anti-tumor effectors and induce tumor regression in vivo...
- Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patientsCedric Menard
Institut National de la Sante et de la Recherche Medicale INSERM, Unit U805 Tumor immunology and immunotherapy, Villejuif, France
Cancer Res 69:3563-9. 2009..The NK cell IFN-gamma production after 2 months of treatment could be considered an independent predictor of long term survival in advanced GISTs treated with IM...
- Dermatologic symptoms associated with the multikinase inhibitor sorafenibCaroline Robert
Department of Medicine, Dermatology Unit, Institut Gustave Roussy, Villejuif, France
J Am Acad Dermatol 60:299-305. 2009..The multikinase inhibitor sorafenib (Nexavar) is associated with a relatively high incidence of dermatologic symptoms...
- Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanomaBernard Escudier
Department of Medicine, Institut Gustave Roussy, Villejuif, France
Clin Cancer Res 13:1801-9. 2007..To determine the safety, maximum tolerated dose, pharmacokinetics, and efficacy, and to evaluate biomarkers, of the multikinase inhibitor sorafenib plus IFN alpha-2a in advanced renal cell carcinoma (RCC) or melanoma...
- Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?Cedric Menard
Center of Clinical Investigations, CBT507, Institut Gustave Roussy, Villejuif, France
Clin Cancer Res 14:5242-9. 2008..However, mechanisms of action and surrogate immunologic markers of efficacy have not been reported thus far...
- ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathwayAhmed Hamai
Institut National de la Sante et de la Recherche Medicale, U753, Laboratoire d Immunologie des Tumeurs Humaines Interaction effecteurs cytotoxiques système tumoral, Institut Gustave Roussy PR1 and IFR 54, Villejuif, France
Cancer Res 68:9854-64. 2008..The present study shows that a shift in ICAM-1 expression, which was associated with an activation of the PI3K/AKT pathway, can be used by metastatic melanoma cells to escape CTL-mediated killing...
- Ipilimumab plus dacarbazine for previously untreated metastatic melanomaCaroline Robert
Institute Gustave, Roussy, Villejuif, France
N Engl J Med 364:2517-26. 2011..We conducted a phase 3 study of ipilimumab (10 mg per kilogram) plus dacarbazine in patients with previously untreated metastatic melanoma...
- Anti-CTLA-4 antibody adjuvant therapy in melanomaAlexander M M Eggermont
Institut d Oncologie Gustave Roussy, Villejuif, France
Semin Oncol 37:455-9. 2010..The EORTC 18071 trial will reach full accrual in 2011 and thus results are expected in 2013 or 2014...
- Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991Alexander M M Eggermont
Institut de Cancerologie Gustave Roussy, Villejuif, France
Eur J Cancer 48:218-25. 2012..Adjuvant interferon has modest activity in melanoma patients at high risk for relapse. Patient selection is important; stage and ulceration of the primary tumour are key prognostic factors...
- Vemurafenib and radiosensitizationLise Boussemart
Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
JAMA Dermatol 149:855-7. 2013..Cutaneous adverse effects are preeminent with UV-A-dependent phototoxicity, hyperkeratotic folliculitis, hand-foot skin reaction, hair changes, verrucous papillomas, keratoacanthomas, and squamous cell carcinomas...
- Gene expression signature associated with BRAF mutations in human primary cutaneous melanomasCaroline Kannengiesser
Service de Génétique and CNRS FRE 2939, Institut Gustave Roussy, Villejuif, France
Mol Oncol 1:425-30. 2008....
- Gap junction communication between autologous endothelial and tumor cells induce cross-recognition and elimination by specific CTLHoussem Benlalam
Institut National de la Santé et de la Recherche Médicale Unite 753, Institut Fédératif de Recherche 54, Villejuif, France
J Immunol 182:2654-64. 2009..Our results indicate that gap junctions facilitate an effective CTL-mediated destruction of endothelial cells from the tumor microenvironment that may contribute to the control of tumor progression...
- Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trialMichele Maio
Michele Maio, University Hospital of Siena, Siena Vanna Chiarion Sileni, Veneto Oncology Institute Istituto Di Ricovero e Cura a Carattere Scientifico, Padova Alessandro Testori, Istituto Europeo di Oncologia, Milan, Italy Jean Jacques Grob, Aix Marseille University, Assistance Publique Hopitaux de Marseille, Hopital Timone, Marseille Luc Thomas, Lyon 1 University, Centre Hospitalier Lyon Sud, Pierre Bénite Caroline Robert, Institute Gustave Roussy, Villejuif, France Steinar Aamdal, Oslo University Hospital and Radium Hospital, Oslo, Norway Igor Bondarenko, Dnepropetrovsk State Medical Academy, Dnepropetrovsk, Ukraine Claus Garbe, University Medical Center, Tubingen, Germany Tai Tsang Chen and Marina Tschaika, Bristol Myers Squibb, Wallingford, CT and Jedd D Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY
J Clin Oncol 33:1191-6. 2015..To demonstrate a long-term survival benefit with ipilimumab, we evaluated the 5-year survival rates of patients treated in a randomized, controlled phase III trial...
- CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patientsPatrick A Ott
Authors Affiliations Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts and Institut Gustave Roussy, Villejuif Paris Sud, Paris, France
Clin Cancer Res 19:5300-9. 2013..Clin Cancer Res; 19(19); 5300-9. ©2013 AACR. ..
- Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancerSandrine Faivre
Department of Medicine, Gustave Roussy Institute, Villejuif, France
J Clin Oncol 24:25-35. 2006..To establish the safety, pharmacokinetics, and recommended dose of sunitinib, a novel oral multitargeting tyrosine kinase inhibitor with antiangiogenic and antitumor properties, in patients with advanced malignancies...
- Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity?Alexander M M Eggermont
Institut de Cancerologie Gustave Roussy, Villejuif, Paris, France
Curr Opin Oncol 24:137-40. 2012..Patients with an ulcerated melanoma do much worse than patients with a nonulcerated melanoma with the same breslow thickness. Ulceration may indicate a separate biologic entity...
- Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell linesHélène Malka-Mahieu
a INSERM U981, Villejuif, France
Cell Cycle 15:2405-9. 2016..Furthermore, inhibiting the eIF4A component of the eIF4F complex, with a small molecule of the flavagline/rocaglate family, synergizes with inhibiting MEK to kill NRAS-mutant cancer cell lines. ..
- Impact of dermatologic adverse events induced by targeted therapies on quality of lifeCécile Charles
Psycho Oncology Unit, Gustave Roussy, Villejuif, France Laboratory of Psychopathology and Health Processes, EA 4057, Psychology Institute, Paris Descartes University Sorbonne Paris Cité, Boulogne Billancourt, France Electronic address
Crit Rev Oncol Hematol 101:158-68. 2016..This article aims to summarize the existing data and to clarify needs in terms of clinical management and future research...
- Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trialBernard Escudier
Department of Immunotherapy, Institut Gustave Roussy, Villejuif, France
J Transl Med 3:10. 2005..MAGE3 specific CD4+ and CD8+ T cell responses could not be detected in peripheral blood. CONCLUSION: The first exosome Phase I trial highlighted the feasibility of large scale exosome production and the safety of exosome administration...
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trialAlexander M M Eggermont
Gustave Roussy Cancer Campus Grand Paris, Villejuif, France Electronic address
Lancet Oncol 16:522-30. 2015..Ipilimumab is an approved treatment for patients with advanced melanoma. We aimed to assess ipilimumab as adjuvant therapy for patients with completely resected stage III melanoma at high risk of recurrence...
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic MelanomaDirk Schadendorf
Dirk Schadendorf, University Hospital Essen, Essen, Germany F Stephen Hodi, Dana Farber Cancer Institute, Boston, MA Caroline Robert, Institute Gustave Roussy, Villejuif, France Jeffrey S Weber, Moffitt Cancer Center, Tampa, FL Kim Margolin, University of Washington, Seattle, WA Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA Debra Patt, The US Oncology Network, McKesson Specialty Health, Houston, TX Tai Tsang Chen, Bristol Myers Squibb, Wallingford, CT David M Berman, Bristol Myers Squibb, Lawrenceville, NJ and Jedd D Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY
J Clin Oncol 33:1889-94. 2015..To provide a more precise estimate of long-term survival observed for ipilimumab-treated patients with advanced melanoma, we performed a pooled analysis of overall survival (OS) data from multiple studies...
- Vemurafenib cooperates with HPV to promote initiation of cutaneous tumorsMatthew Holderfield
Authors Affiliations Novartis Institutes for BioMedical Research, Emeryville UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California Dermatology Unit and INSERM U 981 Department of Medical Biology and Pathology Laboratory and Biobank INSERM U 981, Institut Gustave Roussy, Villejuif Paris Sud and Unité de Génétique, Papillomavirus et Cancer Humain, Institut Pasteur, Paris, France
Cancer Res 74:2238-45. 2014..Our results argue that HPV cooperates with vemurafenib to promote tumorigenesis, in either the presence or absence of RAS mutations...
- Regulation of gap junctions in melanoma and their impact on Melan-A/MART-1-specific CD8⁺ T lymphocyte emergenceHoussem Benlalam
Institut National de la Santé et de la Recherche Médicale INSERM U753, Institut Fédératif de Recherche 54 IFR54, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805, Villejuif, France
J Mol Med (Berl) 91:1207-20. 2013..These findings indicate that Cx43 does not affect lytic function of differentiated CTL, but reveal a major role for GJs in the regulation of antigen CD8(+)-naïve T lymphocyte activation...
- [Detection of residual microscopic disease in melanoma: interest of the sentinel lymph node procedure?]Christine Mateus
Universite Paris Sud, Service de Dermatologie, Gustave Roussy, 114, rue Edouard Vaillant, 94805 Villejuif Cedex, France
Bull Cancer 101:354-7. 2014..Other trials probably more attractive (anti-CTLA4, BRAF and MEK inhibitors), with molecules recently approved in metastatic phase are also ongoing. ..
- Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responsesStephan Roux
INSERM U805, Villejuif, France
Cancer Immunol Immunother 57:1291-300. 2008..We addressed whether tumor-associated antigens released after ECT could induce an efficient systemic immunity when associated with an appropriate immunoadjuvant...
- Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinibGuillaume Bollée
APHP, Service de Néphrologie Adulte, Hopital Necker, Paris, France
Nephrol Dial Transplant 24:682-5. 2009..The patient was given irbesartan, and sunitinib was continued for 3 months after diagnosis. Over this period, blood pressure and renal function remained stable and proteinuria became undetectable...
- New drugs in melanoma: it's a whole new worldAlexander M M Eggermont
Institut de Cancerologie Gustave Roussy, Villejuif, Paris Sud, France
Eur J Cancer 47:2150-7. 2011..Adjuvant trials with BRAF and MEK inhibitors are in the planning phase. Never was there a more exciting period in the world of melanoma treatment...
- Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF-CRAF HeterodimerizationLise Boussemart
Departement de Medecine Oncologique, Gustave Roussy, Villejuif, France INSERM, U981, Villejuif, France
Cancer Res 76:1476-84. 2016..Our findings reveal that BRAF-CRAF complex formation is significantly associated with BRAFi treatment, and may therefore serve as a useful biomarker of BRAFi-induced cutaneous and extracutaneous tumor formation...
- Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samplesVladimir Lazar
Department of Functional Genomics, Institut Gustave Roussy, University Paris Sud, Villejuif, France
Invest New Drugs 32:312-22. 2014..The objective of this study was also to validate functional parameters of DCE-US as surrogate markers to predict earlier response...
- Severe meningo-radiculo-neuritis associated with ipilimumabFlavie Bompaire
Service de Neurologie, Hôpital d Instruction des Armées du Val de Grâce, service de santé des armées, Paris, France
Invest New Drugs 30:2407-10. 2012..In phase III trials, ipilimumab was shown to be the first agent to improve survival in advanced melanoma patients, regardless of previous treatment. We report a case of severe neurologic disease after ipilimumab treatment...
- [Major therapeutic advances in the treatment of metastatic melanoma]Christine Mateus
Institut Gustave Roussy, Service de Dermatologie, 39, rue Camille Desmoulins, 94805 Villejuif, France
Bull Cancer 99:619-25. 2012..New combination therapies and additional targeted and immunotherapy agents are exciting perspectives that make us more optimistic for the future of metastatic melanoma treatment...
- [Epithelial and melanic skin tumours]Christine Mateus
Service de Dermatologie, Institut Gustave Roussy, Villejuif Cedex
Rev Prat 57:2067-79. 2007
- Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With PembrolizumabCamille Hua
Department of Dermatology, Cancer Campus, Gustave Roussy Institute, Villejuif, France
JAMA Dermatol 152:45-51. 2016..Vitiligo is an autoimmune skin disorder that reacts against melanocytes. The association of vitiligo with tumor response in patients with melanoma who undergo immunotherapy has been reported but is still controversial...
- Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-lJean Jacques Grob
Service de Dermatologie, Aix Marseille University, and Assistance Publique Hôpitaux de Marseille APHM, University Hospital Timone, Marseille, France Electronic address
Lancet Oncol 16:1389-98. 2015..Here, we present the effects of treatments on health-related quality of life (HRQoL), an exploratory endpoint in the COMBI-v study...
- Kidney injuries related to ipilimumabHassane Izzedine
Department of Nephrology, Pitie Salpetriere, 47 80 Boulevard de l Hôpital, 75013, Paris, France
Invest New Drugs 32:769-73. 2014..Autoimmune symptoms have to be carefully checked for patients treated with CTLA-4 inhibitors. In order to reduce the risk of sequelae, early recognition of irAEs and treatment initiation are crucial. ..
- Targeted therapy-induced radiation recallAntonin Levy
Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France
Eur J Cancer 49:1662-8. 2013..A diverse range of chemotherapies has been associated with RR but no case series with targeted therapies (TT) has been reported...
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiotaMarie Vetizou
Institut de Cancérologie Gustave Roussy Cancer Campus GRCC, 114 rue Edouard Vaillant, 94805 Villejuif, France INSERM U1015, GRCC, Villejuif, France University of Paris Sud XI, Kremlin Bicetre, France
Science 350:1079-84. 2015..fragilis with anticancer properties. This study reveals a key role for Bacteroidales in the immunostimulatory effects of CTLA-4 blockade. ..
- Nail toxicities induced by systemic anticancer treatmentsCaroline Robert
Gustave Roussy, Département de Médicine Oncologique, Service de Dermatologie, Villejuif, France Université Paris Sud, Faculte de Medecine, Le Kremlin Bicetre, France Electronic address
Lancet Oncol 16:e181-9. 2015..We review the nail changes induced by conventional chemotherapies and those associated with the use of targeted anticancer drugs and discuss preventive or curative options. ..
- Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapiesAlexander M M Eggermont
Gustave Roussy Cancer Campus Grand Paris and University Paris Sud, Paris, France Electronic address
Semin Oncol 42:429-35. 2015..An adjuvant trial to evaluate pembrolizumab in this population (EORTC 1325) was started in early 2015...
- [Immunotherapies and melanoma]Emilie Routier
Gustave Roussy, Service de Dermatologie, 114, rue Edouard Vaillant, 94805 Villejuif Cedex, France Electronic address
Bull Cancer 101:S13-24. 2014..The challenge for the next years will be to optimize these new strategies, by possibly using these new drugs sequentially or in combination for a higher clinical benefit for our patients. ..
- Immunotherapies and melanomaEmilie Routier
Gustave Roussy, Service de Dermatologie, 114, rue Edouard Vaillant, 94805 Villejuif Cedex, France
Bull Cancer 101:13-24. 2014..The challenge for the next years will be to optimize these new strategies, by possibly using these new drugs sequentially or in combination for a higher clinical benefit for our patients. ..
- Update on the role of ipilimumab in melanoma and first data on new combination therapiesMichele Maio
Medical Oncology and Immunotherapy, Azienda Ospedaliera Universitaria Senese, Istituto Toscano Tumori, Siena, Italy
Curr Opin Oncol 25:166-72. 2013..This article provides an update on the therapeutic role of the monoclonal antibody ipilimumab in melanoma. Recent therapeutic combinations, as well as directions for further investigations, will also be discussed...
- Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanomaMojgan Movassagh
Immunology Institut National de la Santé et de la Recherche Médicale ERM0208 and Immunotherapy Unit, Department of Pathology, Dermatology Unit, Institut Gustave Roussy, 94805 Villejuif Cedex, France
Cancer Res 64:2192-8. 2004....
- Imaging of melanoma: usefulness of ultrasonography before and after contrast injection for diagnosis and early evaluation of treatmentLinda Chami
Imaging Department Institut Gustave Roussy, Villejuif, France
Clin Cosmet Investig Dermatol 4:1-6. 2011....
- [Not Available]Christine Mateus
Service de Dermatologie, Gustave Roussy, Université Paris Saclay, Departement de Medecine Oncologique, Villejuif, F 94805, France Electronic address
Bull Cancer 103:S4-S11. 2016....
- Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25Dalil Hannani
1 Gustave Roussy Cancer Campus, Villejuif, France 2 INSERM U1015, Villejuif, France 3 Université Paris Sud XI, Faculte de Medecine, Le Kremlin Bicetre, France
Cell Res 25:208-24. 2015..Importantly, our study provides the first immunologically relevant biomarker, namely elevated serum sCD25, that predicts resistance to CTLA-4 blockade in patients with melanoma. ..
- [Axitinib in metastatic renal carcinomas: update of knowledge about side effects]Laurence Albiges
Institut Gustave Roussy, Departement d Oncologie Medicale, 39, rue Camille Desmoulins, 94805 Villejuif Cedex, France
Bull Cancer 101:976-88. 2014..The objective of this article is to summarize the knowledge as for the side effects related to axitinib in terms of incidence, etiology and symptoms for the effects requiring a specific management...
- Side effects and toxicities of targeted therapies in stage IV melanomaPaolo A Ascierto
1Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori Fondazione G Pascale, Naples, Italy 2Odense University Hospital, Odense, Denmark 3Newcastle University, Newcastle, Australia 4Instituto de Oncologia Angel Rolfo, Buenos Aires, Argentina 5Institut Gustave Roussy, Villejuif, France 6University of Kiel, Kiel, Germany 7Hospital La Paz, Madrid, Spain and 8Institut Gustave Roussy, Villejuif, France
Am J Ther 22:44-53. 2015..With new treatment opportunities come increased chance of toxic reactions. The key to successful melanoma treatment in the future is likely to be novel combinations of new therapeutic agents. ..
- Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effectsChristophe Borg
Department of Clinical Biology, Equipe de Recherche Mixte 0208, INSERM, Institut Gustave Roussy, Villejuif, France
J Clin Invest 114:379-88. 2004..These data point to a novel mode of antitumor action for Gleevec...
- RAF inhibition and induction of cutaneous squamous cell carcinomaCaroline Robert
Department of Medicine, Gustave Roussy Institute, Villejuif, France
Curr Opin Oncol 23:177-82. 2011..The purpose of this review is to discuss the mechanisms as well as the management and implications of this unexpected side-effect...
- [Management of recurrent soft tissue sarcoma of the retroperitoneum]Sylvie Bonvalot
Departement de Chirurgie, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif
Bull Cancer 91:845-52. 2004..Adequate management at the time of primary presentation is likely to afford the best chance for long-term survival...
- Thyroid adenomas and carcinomas following radiotherapy for a hemangioma during infancyNadia Haddy
INSERM, U605, Villejuif, France
Radiother Oncol 93:377-82. 2009..This paper presents the incidence of differentiated thyroid adenomas and carcinomas after radiotherapy in this cohort...
- Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?Caroline Robert
Ann Intern Med 143:313-4. 2005
- Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 casesFlorent Grange
Department of Dermatology, Hopital Robert Debre, avenue du Général Koenig, Reims 51100, France
Arch Dermatol 143:1144-50. 2007....
- Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patientsNadege Bercovici
IDM, Hopital Europeen Georges Pompidou, Unité d Immunologie Biologique, EA 4054 Université Paris, France
J Immunother 31:101-12. 2008..The differential expression of perforin and IFN-gamma by antitumor and antiviral CD8+ T cells supports that the sole use of IFN-gamma production to monitor T cells overlooks functional T-cell subpopulations triggered by vaccines...
- CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent mannerFrancois Ghiringhelli
ERM 0208, Institut National de la Sante et de la Recherche Medicale INSERM, University of Paris XI, France
J Exp Med 202:1075-85. 2005..Human NK cell-mediated tumor recognition could also be restored by depletion of T reg cells from tumor-infiltrating lymphocytes. These findings support a role for T reg cells in blunting the NK cell arm of the innate immune system...